Precigen Inc (PGEN)

$3.12 -0.07 (-2.19%)
Market Cap 950.53M
Revenue (ttm) 3.93M
Net Income (ttm) -126.24M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -3,212.21%
Debt to Equity Ratio 0.00
Volume 7,963,400
Avg Vol 10,507,624
Day's Range N/A - N/A
Shares Out 297.97M
Stochastic %K 18%
Beta 1.61
Analysts Strong Sell
Price Target $8.25

Company Profile

Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine an...

Industry: Biotechnology
Sector: Healthcare
Phone: 301 556 9900
Address:
20374 Seneca Meadows Parkway, Germantown, United States
inflect1on
inflect1on Oct. 10 at 10:03 PM
$PGEN 2.9 trapdoor getting very close, what a wrench thrown our way today smfh
1 · Reply
M22
M22 Oct. 10 at 9:25 PM
$PGEN no worries.👍 I like the stock 💎🤲
0 · Reply
OmFm
OmFm Oct. 10 at 8:18 PM
$PGEN Maybe if you are a good boy you can buy it at $2. Keep the faith.
0 · Reply
BOXLinvestor
BOXLinvestor Oct. 10 at 6:08 PM
$PGEN Precigen (option volume 10-10-25) 3.04 -2.6% | 81 trades | total $106.1K | 90-day avg $345.9K × 0.31 call $66K | put $40.1K | 96% single-leg, 4% multi-leg
0 · Reply
GA09
GA09 Oct. 10 at 2:37 PM
$PGEN We need some really good news to stop the slow bleed. Should have sold at $5. Had no idea I could buy it back at $3.
2 · Reply
MakeM0ney_444
MakeM0ney_444 Oct. 9 at 6:54 PM
$PGEN what is the catalyst here? This has been dead money for months
3 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 9 at 4:02 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $PGEN Current Share Price: $3.22 Contracts: $PGEN January 15, 2027 $4 Calls Scale in: $1.35- $1.65 Scale out: $2.10-$2.70 Can Easily Capture: 60% ROI Blended DTE: 463 Days | Join Elites here: https://liquidtheta.com/
0 · Reply
Cascas007
Cascas007 Oct. 9 at 3:43 PM
$PGEN All, based on the latest filing, Kirk + Miller owns 48% of the outstanding shares. Bill Miller, a value investor, holding 9% of the shares is a big deal. Go long for the long term!
1 · Reply
allout06
allout06 Oct. 9 at 1:24 PM
My win rate for the past 3 months is sitting between 70%-78%! Sharpe ratio is a 1.95. Watching $PGEN carefully! Buying in the bright green box if we get the correct price action. Its 120% back to the most recent highs from there!
1 · Reply
Jason_Craps
Jason_Craps Oct. 9 at 10:30 AM
$PGEN @rubraquercus You have so hurt my feelings. Master Trader, if you sold, why are you still posting here?
0 · Reply
Latest News on PGEN
Precigen Announces Up to $125 Million Non-Dilutive Financing

Sep 3, 2025, 7:00 AM EDT - 5 weeks ago

Precigen Announces Up to $125 Million Non-Dilutive Financing

Precigen, Inc. - Special Call

Sep 2, 2025, 1:55 PM EDT - 5 weeks ago

Precigen, Inc. - Special Call

Precigen to Participate in Upcoming Virtual Fireside Chats Hosted by Cantor and H.C. Wainwright

Aug 25, 2025, 8:05 AM EDT - 6 weeks ago

Precigen to Participate in Upcoming Virtual Fireside Chats Hosted by Cantor and H.C. Wainwright

Undercovered Dozen: Precigen, ONEOK, Bitmine And More

Aug 22, 2025, 10:43 AM EDT - 7 weeks ago

Undercovered Dozen: Precigen, ONEOK, Bitmine And More

BMNR OKE

Precigen: This Billion-Dollar Approval Is Still Undervalued

Aug 15, 2025, 3:15 PM EDT - 2 months ago

Precigen: This Billion-Dollar Approval Is Still Undervalued

Why Is Precigen Stock Surging On Friday?

Aug 15, 2025, 9:48 AM EDT - 2 months ago

Why Is Precigen Stock Surging On Friday?

US FDA approves Precigen's immunotherapy for rare respiratory disease

Aug 15, 2025, 7:18 AM EDT - 2 months ago

US FDA approves Precigen's immunotherapy for rare respiratory disease

Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis

Aug 15, 2025, 7:00 AM EDT - 2 months ago

Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis

Precigen: August Is Pivotal For This Biotech Innovator

Jul 7, 2025, 5:58 PM EDT - 3 months ago

Precigen: August Is Pivotal For This Biotech Innovator

Precigen Reports First Quarter 2025 Financial Results and Business Updates

May 14, 2025, 4:05 PM EDT - 5 months ago

Precigen Reports First Quarter 2025 Financial Results and Business Updates

Precigen and Recurrent Respiratory Papillomatosis Foundation to Host the 2025 International RRP Awareness Day on June 11th

Apr 16, 2025, 8:05 AM EDT - 6 months ago

Precigen and Recurrent Respiratory Papillomatosis Foundation to Host the 2025 International RRP Awareness Day on June 11th

Precigen, Inc. (PGEN) Q4 2024 Earnings Call Transcript

Mar 19, 2025, 7:47 PM EDT - 7 months ago

Precigen, Inc. (PGEN) Q4 2024 Earnings Call Transcript

Precigen Reports Full Year 2024 Financial Results and Business Updates

Mar 19, 2025, 4:05 PM EDT - 7 months ago

Precigen Reports Full Year 2024 Financial Results and Business Updates

Precigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19th

Mar 13, 2025, 8:05 AM EDT - 7 months ago

Precigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19th

Precigen: UltraCAR-T Development Brings Another Side Of Pipeline Advancement

Feb 28, 2025, 8:56 AM EST - 8 months ago

Precigen: UltraCAR-T Development Brings Another Side Of Pipeline Advancement

FDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025

Feb 25, 2025, 8:05 AM EST - 8 months ago

FDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025

Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 13, 2025, 7:00 AM EST - 9 months ago

Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference

Precigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 9, 2025, 8:30 AM EST - 9 months ago

Precigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis

Dec 30, 2024, 7:00 AM EST - 10 months ago

Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis

Precigen Announces $79.0 Million Private Placement Offering of Convertible Preferred Stock

Dec 27, 2024, 9:00 AM EST - 10 months ago

Precigen Announces $79.0 Million Private Placement Offering of Convertible Preferred Stock

Precigen Reports Third Quarter 2024 Financial Results and Business Updates

Nov 14, 2024, 4:30 PM EST - 11 months ago

Precigen Reports Third Quarter 2024 Financial Results and Business Updates

Precigen to Participate in the Stifel 2024 Healthcare Conference

Nov 12, 2024, 4:05 PM EST - 11 months ago

Precigen to Participate in the Stifel 2024 Healthcare Conference

Precigen to Participate in the 2024 Cantor Global Healthcare Conference

Sep 16, 2024, 4:30 PM EDT - 1 year ago

Precigen to Participate in the 2024 Cantor Global Healthcare Conference

Titan Machinery Reports Weak Preliminary Results, Joins Precigen, Gogoro And Other Big Stocks Moving Lower In Thursday Pre-Market Session

Aug 15, 2024, 8:11 AM EDT - 1 year ago

Titan Machinery Reports Weak Preliminary Results, Joins Precigen, Gogoro And Other Big Stocks Moving Lower In Thursday Pre-Market Session

GGR TITN

Precigen, Inc. (PGEN) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 7:03 PM EDT - 1 year ago

Precigen, Inc. (PGEN) Q2 2024 Earnings Call Transcript

Precigen Reports Second Quarter and First Half 2024 Financial Results and Business Updates

Aug 14, 2024, 4:05 PM EDT - 1 year ago

Precigen Reports Second Quarter and First Half 2024 Financial Results and Business Updates

Precigen to Announce Second Quarter and First Half 2024 Financial Results on August 14th

Aug 9, 2024, 8:00 AM EDT - 1 year ago

Precigen to Announce Second Quarter and First Half 2024 Financial Results on August 14th

Precigen Announces Pricing of $30.0 Million Public Offering of Common Stock

Aug 7, 2024, 9:30 PM EDT - 1 year ago

Precigen Announces Pricing of $30.0 Million Public Offering of Common Stock

Precigen Announces Proposed $30 Million Public Offering of Common Stock

Aug 6, 2024, 4:04 PM EDT - 1 year ago

Precigen Announces Proposed $30 Million Public Offering of Common Stock

Precigen Strategically Prioritizes Portfolio to Focus on First Potential Gene Therapy Launch

Aug 6, 2024, 4:01 PM EDT - 1 year ago

Precigen Strategically Prioritizes Portfolio to Focus on First Potential Gene Therapy Launch

Precigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy Launch

Jul 23, 2024, 8:01 AM EDT - 1 year ago

Precigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy Launch

Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response

Jun 3, 2024, 9:30 AM EDT - 1 year ago

Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response

Precigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent Respiratory Papillomatosis Presented at the 2024 ASCO Annual Meeting

May 23, 2024, 5:00 PM EDT - 1 year ago

Precigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent Respiratory Papillomatosis Presented at the 2024 ASCO Annual Meeting

Precigen Reports First Quarter 2024 Financial Results and Business Updates

May 14, 2024, 4:05 PM EDT - 1 year ago

Precigen Reports First Quarter 2024 Financial Results and Business Updates

Precigen to Announce First Quarter 2024 Financial Results on May 14th and Host a Conference Call on June 3rd following the Late-breaking Oral Presentation for PRGN-2012 at the 2024 ASCO Annual Meeting

May 8, 2024, 4:05 PM EDT - 1 year ago

Precigen to Announce First Quarter 2024 Financial Results on May 14th and Host a Conference Call on June 3rd following the Late-breaking Oral Presentation for PRGN-2012 at the 2024 ASCO Annual Meeting

Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting

Apr 24, 2024, 10:20 AM EDT - 1 year ago

Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting

Actym Therapeutics Appoints Thomas Smart as CEO

Apr 24, 2024, 9:00 AM EDT - 1 year ago

Actym Therapeutics Appoints Thomas Smart as CEO

ANAB XOMA

Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th

Mar 28, 2024, 4:05 PM EDT - 1 year ago

Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th

Precigen, Inc. (PGEN) Q4 2023 Earnings Call Transcript

Mar 19, 2024, 8:49 PM EDT - 1 year ago

Precigen, Inc. (PGEN) Q4 2023 Earnings Call Transcript

Precigen Reports Full Year 2023 Financial Results and Business Updates

Mar 19, 2024, 4:05 PM EDT - 1 year ago

Precigen Reports Full Year 2023 Financial Results and Business Updates

Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis

Mar 12, 2024, 4:05 PM EDT - 1 year ago

Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis

Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th

Mar 5, 2024, 4:05 PM EST - 1 year ago

Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th

Precigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 6, 2024, 4:05 PM EST - 1 year ago

Precigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Precigen: RRP Targeting With AdenoVerse Technology Platform

Jan 19, 2024, 7:39 PM EST - 1 year ago

Precigen: RRP Targeting With AdenoVerse Technology Platform

Precigen Receives Orphan Drug Designation for PRGN-2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission

Jan 16, 2024, 8:05 AM EST - 1 year ago

Precigen Receives Orphan Drug Designation for PRGN-2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission

Precigen Highlights Pipeline Updates to be Presented at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 8, 2024, 8:30 AM EST - 1 year ago

Precigen Highlights Pipeline Updates to be Presented at the 42nd Annual J.P. Morgan Healthcare Conference

Precigen to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 18, 2023, 4:05 PM EST - 1 year ago

Precigen to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Precigen to Participate in the JMP Securities Hematology and Oncology Summit

Nov 29, 2023, 4:05 PM EST - 2 years ago

Precigen to Participate in the JMP Securities Hematology and Oncology Summit

Precigen Reports Third Quarter 2023 Financial Results and Progress of Clinical Programs

Nov 9, 2023, 4:55 PM EST - 2 years ago

Precigen Reports Third Quarter 2023 Financial Results and Progress of Clinical Programs

Precigen to Participate in the Stifel 2023 Healthcare Conference

Nov 7, 2023, 4:05 PM EST - 2 years ago

Precigen to Participate in the Stifel 2023 Healthcare Conference

inflect1on
inflect1on Oct. 10 at 10:03 PM
$PGEN 2.9 trapdoor getting very close, what a wrench thrown our way today smfh
1 · Reply
M22
M22 Oct. 10 at 9:25 PM
$PGEN no worries.👍 I like the stock 💎🤲
0 · Reply
OmFm
OmFm Oct. 10 at 8:18 PM
$PGEN Maybe if you are a good boy you can buy it at $2. Keep the faith.
0 · Reply
BOXLinvestor
BOXLinvestor Oct. 10 at 6:08 PM
$PGEN Precigen (option volume 10-10-25) 3.04 -2.6% | 81 trades | total $106.1K | 90-day avg $345.9K × 0.31 call $66K | put $40.1K | 96% single-leg, 4% multi-leg
0 · Reply
GA09
GA09 Oct. 10 at 2:37 PM
$PGEN We need some really good news to stop the slow bleed. Should have sold at $5. Had no idea I could buy it back at $3.
2 · Reply
MakeM0ney_444
MakeM0ney_444 Oct. 9 at 6:54 PM
$PGEN what is the catalyst here? This has been dead money for months
3 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 9 at 4:02 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $PGEN Current Share Price: $3.22 Contracts: $PGEN January 15, 2027 $4 Calls Scale in: $1.35- $1.65 Scale out: $2.10-$2.70 Can Easily Capture: 60% ROI Blended DTE: 463 Days | Join Elites here: https://liquidtheta.com/
0 · Reply
Cascas007
Cascas007 Oct. 9 at 3:43 PM
$PGEN All, based on the latest filing, Kirk + Miller owns 48% of the outstanding shares. Bill Miller, a value investor, holding 9% of the shares is a big deal. Go long for the long term!
1 · Reply
allout06
allout06 Oct. 9 at 1:24 PM
My win rate for the past 3 months is sitting between 70%-78%! Sharpe ratio is a 1.95. Watching $PGEN carefully! Buying in the bright green box if we get the correct price action. Its 120% back to the most recent highs from there!
1 · Reply
Jason_Craps
Jason_Craps Oct. 9 at 10:30 AM
$PGEN @rubraquercus You have so hurt my feelings. Master Trader, if you sold, why are you still posting here?
0 · Reply
Norny44
Norny44 Oct. 9 at 6:39 AM
$PGEN Without an update or some sort of catalyst we could be heading below 3 very quickly.!!. Short interest is still high here.
1 · Reply
Kid_Shelleen
Kid_Shelleen Oct. 9 at 1:33 AM
$PGEN so glad I sold in the 4s
1 · Reply
Lincoln1962
Lincoln1962 Oct. 9 at 12:14 AM
$PGEN Wow
0 · Reply
Bio_Invest101
Bio_Invest101 Oct. 8 at 11:19 PM
$PGEN Understandably Many people are upset that Kirk sold a lot of his shares but it’s worth noting that the new big 9.2% ownership too 2025-09-23 - Miller William H III has filed an SCHEDULE 13G form with the Securities and Exchange Commission (SEC) disclosing ownership of 34,051,925 shares of Precigen, Inc. (US:PGEN). This represents 9.2 percent ownership of the company.
0 · Reply
Kid_Shelleen
Kid_Shelleen Oct. 8 at 10:26 PM
$PGEN this was a flash in the pan.
1 · Reply
BioStick123
BioStick123 Oct. 8 at 4:09 PM
$PGEN should get back into 3.75-4.00 range.
2 · Reply
GFstocktwits
GFstocktwits Oct. 8 at 10:52 AM
$PGEN 2.94 would be a nice pullback
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 8 at 7:33 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $PGEN Current Share Price: $3.29 Contracts: $PGEN January 15, 2027 $4 Calls Scale in: $1.09- $1.33 Scale out: $1.70-$2.18 Can Easily Capture: 60% ROI Blended DTE: 465 Days | Join Elites here: https://liquidtheta.com/
0 · Reply
updownsides
updownsides Oct. 8 at 3:56 AM
$PGEN
0 · Reply
JunkPost
JunkPost Oct. 7 at 7:01 PM
$PGEN Some Good News due I guess
1 · Reply
Norny44
Norny44 Oct. 7 at 5:51 PM
$PGEN 2pm take off
0 · Reply
inflect1on
inflect1on Oct. 7 at 4:39 PM
$PGEN r/r much sweeter here versus 3.6-4, what a gift. No greed chasing, or when looking for entries. Thanks Mr. Market
0 · Reply